ZA979425B - Pharmaceutical composition for rapid suspension in aqueous media - Google Patents

Pharmaceutical composition for rapid suspension in aqueous media

Info

Publication number
ZA979425B
ZA979425B ZA979425A ZA979425A ZA979425B ZA 979425 B ZA979425 B ZA 979425B ZA 979425 A ZA979425 A ZA 979425A ZA 979425 A ZA979425 A ZA 979425A ZA 979425 B ZA979425 B ZA 979425B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
aqueous media
rapid suspension
suspension
rapid
Prior art date
Application number
ZA979425A
Other languages
English (en)
Inventor
Massimo Maria Calanchi
Marco Giuseppe Raffael Marconi
Luigi Giovanni Mapelli
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of ZA979425B publication Critical patent/ZA979425B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA979425A 1996-10-23 1997-10-21 Pharmaceutical composition for rapid suspension in aqueous media ZA979425B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9622090A GB2318511A (en) 1996-10-23 1996-10-23 Process for the preparation of a pharmaceutical composition for rapid suspension in water

Publications (1)

Publication Number Publication Date
ZA979425B true ZA979425B (en) 1999-04-21

Family

ID=10801863

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA979425A ZA979425B (en) 1996-10-23 1997-10-21 Pharmaceutical composition for rapid suspension in aqueous media

Country Status (9)

Country Link
US (1) US6261602B1 (xx)
EP (1) EP0936901A1 (xx)
JP (1) JP4129995B2 (xx)
AR (1) AR008895A1 (xx)
AU (1) AU725958B2 (xx)
CA (1) CA2268626C (xx)
GB (1) GB2318511A (xx)
WO (1) WO1998017250A1 (xx)
ZA (1) ZA979425B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184220B1 (en) 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
US6794411B1 (en) 1999-04-06 2004-09-21 Laboratoire Des Produits Ethiques Ethypharm Drinkable ibuprofen pharmaceutical suspension
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US6596708B1 (en) 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
BR0309093A (pt) * 2002-04-09 2005-02-09 Flamel Tech Sa Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
ATE541562T1 (de) * 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
BG738Y1 (bg) * 2002-07-02 2005-05-31 Balkanfarma Razgrad Ad Лекарствена форма
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US20070053981A1 (en) * 2003-07-11 2007-03-08 Eva Blychert Solid composition comprising a proton pump inhibitor
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) * 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
MY158981A (en) 2008-07-31 2016-11-30 Shaklee Corp Method of preparing a muscadine pomace extract
US9173916B2 (en) 2008-07-31 2015-11-03 Shaklee Corporation Method of preparing a muscadine pomace extract
MY155394A (en) 2008-07-31 2015-10-15 Shaklee Corp Muscadine composition with improved anti-oxidant activity
US9132162B2 (en) 2008-07-31 2015-09-15 Shaklee Corporation Muscadine compositions with anti-oxidant activity
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
BRPI1007379B8 (pt) 2009-01-06 2022-07-19 Curemark Llc composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN102647971B (zh) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
BR112012022073A2 (pt) 2010-03-03 2017-10-31 Boehringer Ingelheim Vetmedica Gmbh uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US20170000727A1 (en) 2013-12-20 2017-01-05 Disphar International B.V. Dry enema product
WO2016154313A1 (en) * 2015-03-24 2016-09-29 Zywie, Llc High drug loading liquid oral pharmaceutical compositions
WO2018017608A1 (en) 2016-07-19 2018-01-25 Shaklee Corporation Muscadine topical composition with low content of condensed tannin molecules
BR112023000598A2 (pt) 2020-07-15 2023-01-31 Schabar Res Associates Llc Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.

Also Published As

Publication number Publication date
US6261602B1 (en) 2001-07-17
JP4129995B2 (ja) 2008-08-06
CA2268626C (en) 2007-03-06
GB2318511A (en) 1998-04-29
AR008895A1 (es) 2000-02-23
GB9622090D0 (en) 1996-12-18
CA2268626A1 (en) 1998-04-30
AU5188798A (en) 1998-05-15
WO1998017250A1 (en) 1998-04-30
AU725958B2 (en) 2000-10-26
JP2000508342A (ja) 2000-07-04
EP0936901A1 (en) 1999-08-25

Similar Documents

Publication Publication Date Title
ZA979425B (en) Pharmaceutical composition for rapid suspension in aqueous media
ZA9810490B (en) 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
HUP9901192A3 (en) Contrast media
EP0763099A4 (en) MICROBIOLOGICAL ENVIRONMENT
PL328406A1 (en) Improved contrast media
IL122447A0 (en) Pharmaceutical composition with anaestheric effect
HUP0000564A3 (en) Pharmaceutical composition in form of oil suspension
EP0864022A4 (en) SUB-BEAM FOR CONSTRUCTION
GB9815532D0 (en) Pharmaceutical suspension formulation
GB9603547D0 (en) Contrast media
GB9705035D0 (en) Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
AUPM930494A0 (en) Polymerization in aqueous media
ZA971132B (en) New cephem compounds and pharmaceutical use thereof.
GB9606579D0 (en) Pharmaceutical composition and methods for the manufacture thereof
GB9623962D0 (en) Pharmaceutical composition
GB2286392B (en) Piperazine derivatives and pharmaceutical uses thereof
HUP9903870A3 (en) Piperazine derivatives and process for the preparation thereof
PH30175A (en) Aqueous pharmaceutical suspension for pharmaceutical actives
ZA976543B (en) Piperazine derivatives and process for the preparation thereof.
GB9418285D0 (en) DNA replication
GB9602152D0 (en) Contrast media
HU9803035D0 (en) 7-bromo- and 7,7-dibromo-cepham and cephem derivatives
GB9405025D0 (en) Pharmaceutical composition
HU9400523D0 (en) Pharmaceutical composition
ZA953965B (en) Pharmaceutical composition